Cincinnati Children’s Hospital Medical Center is conducting a unique clinical trial involving just a single dose. The study will explore the effects of Gaboxadol and its potential to alter the brain’s response to sound. Additionally, this trial will assess the feasibility of conducting research assessments from the comfort of participants’ homes.
About the Study
Who can participate?
Adult men ages 18-40 years old with a diagnosis of Fragile X syndrome may be eligible to participate.
What will happen in the study?
If the individual qualifies and decides to participate in this research study, they will complete a total of 4 visits over the course of 8 weeks. 2 of the visits are completed at Cincinnati Children’s Hospital Medical Center and 2 visits are completed in the participant’s home.
The following is a list of some of the things that will happen during the study:
- Blood draws
- EEG tasks
- Cognitive testing
- Neuropsychological games
- Parent-reported measures
What are the good things that can happen from this research?
We cannot promise any benefits to you or others from your taking part in this research. We hope the information learned from this study will benefit others with FXS in the future. Information gained from this research could lead to better treatments for FXS.
What are the bad things that can happen from this research?
There are minimal risks associated with Gaboxadol. These include: drowsiness, headache and nausea. However, the study team will take all necessary precautions to minimize these risks.
There may be other risks that we do not know about yet.
Will I or my child be paid to complete this study?
Participants receive $100 at every visit ($400 total). Travel reimbursement may be available for eligible families.
Interested in Participating?
Our Most Recent Opportunities
Study: Somatic symptom development in 6-12 year old females with an FMR1 mutation (SoS Study)
Researchers at the New York State Institute for Basic Research are conducting a study to better understand the development of physical (somatic) symptoms in females living with and without an FMR1 gene variation.
FXS TECH Study
Researchers at Rush University Medical Center are working on technology to improve how to identify and track progress in children living with autism and Fragile X syndrome. The study is currently recruiting children ages 18 months to 5 years, and 12-18 years.
Study: Web Intervention for Parents of Youth with Genetic Syndromes (WINGS)
Researchers at the Autism Assessment, Research, Treatment & Services (AARTS) Center at Rush University Medical Center are currently conducting a fully-virtual research study that is testing two telehealth interventions that are designed to help parents of children with genetic syndromes and intellectual disabilities gain strategies to manage challenging behaviors.
Neural Underpinnings of the Relationship Between Cognition and Gait Dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
Movement disorders researchers at Rush University Medical Center are conducting a research study to learn about brain activation in people living with FXTAS during tasks like walking and thinking. This study is currently recruiting adults ages 50+ who are living with FXTAS.
Pharmacogenomics and the Fragile X Community: Interest and Prior Understanding
Researchers at the University of Alabama are looking for members of the FX community to take their online survey so they can explore the knowledge & opinions of the FXS community on pharmacogenomic testing.
Brain & Behavior Study
Researchers at Purdue University are conducting a natural history research study to learn about brain activity in females, ages18-60 years, living with the FMR1 premutation.